AZD7789

Phase 2Small molecule

AstraZeneca

AZD7789 is one of 61 small molecule programs targeting Advanced or Metastatic NSCLC. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced or Metastatic NSCLCActive, not recruiting

Safety and EfficacyActive, not recruiting

Advanced or Metastatic NSCLCPhase 1

Active, not recruiting

Safety and EfficacyPhase 2

Active, not recruiting

Competition

Competitive Landscape

149 competitors in Safety and Efficacy

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 3

8 2

Opdivo

Bristol-Myers Squibb

Phase 3

7 3

Humira

Novartis

Phase 3

3 4

Avastin

Roche

Phase 3

3 5

BEYFORTUS

Sanofi

Phase 3

1 6

Oncovin

Eli Lilly

Phase 3

1 7

Neulasta

Amgen

Phase 3

1 8

Adriamycin

Pfizer

Phase 3

1 9

Cytoxan

BBaxter Healthcare Corporation

Phase 3

6 10

Rayos

RRoxane Laboratories

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Active, not recruiting

Advanced or Metastatic NSCLC

NCT04612751

Clinical

Trials by Indication[1]

Safety and Efficacy1 trial

A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 1/2·NCT04931654·136 enrolled

Advanced or Metastatic NSCLC1 trial

A Phase 1b, Multicenter, 2-Part, Open-Label Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Immunotherapy With or Without Carboplatin in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (Tropion-Lung04)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 1·NCT04612751·155 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for AZD7789. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AZD7789 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AZD7789. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AstraZeneca

AZD7789

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Safety and Efficacy1 trial

Advanced or Metastatic NSCLC1 trial

References

Drug Info

Quick Facts

Related News